# Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

> **NCT02097732** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Melanoma
- Brain Metastases

## Interventions

- **DRUG:** Ipilimumab
- **PROCEDURE:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT02097732
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-08
- **Final completion:** 2020-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study halted prematurely due to a change in the standard of care treatment
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097732, "Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02097732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*